iCardiac Technologies announced the implementation of its quality metric--Method Bias Sensitivity (MBS)--into its Phase I QT assessment services. The metric compares the automated measurements from a timepoint to the measurements/values derived by that core lab’s methodology that was used for that particular study. Other metrics are under discussion by the Cardiac Safety Research Consortium members, however, iCardiac is implementing its metric after the ICH E14 http://www.appliedclinicaltrialsonline.com/alternative-path-tqt-studies approved a lower-cost approach to TQT studies for cardiac safety assessment.
Read the full release here
